HOXA5 and cancer: HOXA5, which is identified as a novel target of TRAF7, has been demonstrated to bind directly to the SPRY2 promoter and subsequently regulate the MEK/ERK signaling pathway, thus to affect PCa proliferation, metastasis, and cancer stemness.